Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas. by Rehn, S. et al.
Brils Jou dCmw(1395)71,1099-1105
© 1995Stokton Press Al rihts reserved 0007-0920/95$12.00
Deoxythymidine kinase in the tumour cells and serum of patients with
non-Hodgkin lymphomas
S Rehn', JS Gronowitz2, C Killander2, C Sundstr6m3 and B Glimelius'
'Department ofOncology, University ofUppsala, Akademiska sjukhuset, S-751 85 Uppsala, Sweden; 2Research Unit ofReplication
Enzymology, Biomedical Centre, University ofUppsala, S-751 23 Uppsala, Sweden; 3Department ofPathology, University of
Uppsala, Akademiska sjukhuset, S-751 85 Uppsala, Sweden.
Sary The levels of deoxythymidine kinase in tumour cells (C-TK) and in serum (S-TK) were investigated
and the tumour volume cakulated in 89 patients with non-Hodgkin lymphoma (NHL), in order to ascertain
the importance of C-TK and tumour burden as regards the S-TK levels. Among all patients, a correlation was
seen between S-TK and tumour volume but not between S-TK and C-TK. However, within different tumour
volume categories (small, medium-sized and large), there was a correlation between S-TK and C-TK. Multiple
regresson analysis supported this notion. C-TK correlated with the proliferation-associated parameters,
S-phase fraction and mitotic index. As already known, S-TK was found to have a strong prognostic value.
C-TK and tumour burden were also of prognostic value. In multivariate analyses, C-TK and tumour volume
did not provide prognostic information in addition to S-TK, whereas, in the absence of S-TK, C-TK and
tumour volume did provide additional information. It is conclue that the serum level of TK depends on
both the tumour burden and the tumour cell proliferation rate. Based upon estimations of S-TK in patients
assessed shortly after chemotherapy, we also suggest that S-TK reflects the number of proliferating cells that
have died during the period immediately before sampling.
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During cell proliferation, new DNA is synthesised. The syn-
thesis of deoxythymidine triphosphate for DNA synthesis is
either via the de novo pathway or via introduction of
thymidine by means of thymidine kinase (TK). This enzyme,
which is the only enzyme capable of introducing thymidine
production, catalyses the phosphorylation of deoxythymidine
to deoxythymidine monophosphate. Intracellular levels of
TK increase when cells enter the late G, phase and decrease
at mitosis (Sherley et al., 1988).
Severeal studies have shown the prognostic value of the
serum level of deoxythymidine kinase (S-TK) in non-
Hodgkdn lymphomas (NHL) (Ellims et al., 1981; Gronowitz
et al., 1983; Hagberg et al., 1984a; Martinsson et al., 1988;
Rehn et al., 1991) and in other tumour types such as Hodg-
kin's disease (Eriksson et al., 1985), acute non-lymphoblastic
leukaemia (Archimbaud et al., 1988), small-cell lung cancer
(Gronowitz et al., 1986; van der Gaast et al., 1991), multiple
myeloma (Simonsson et al., 1988; Luoni et al., 1991),
adenocarcinoma of the breast (Romain et al., 1990) and
prostatic adenocarcinoma (Lewenhaupt et al., 1990). In
NHL, the S-TK level has in several studies been the strongest
prognostic factor when compared with other serum markers,
proliferation-associated parameters and clinical variables
(Hagberg et al., 1984a; Martnsson et al., 1988; Rehn et al.,
1991). A study by Eng Gan et al. (1984) has indicated that
the cellular levels of TK (C-TK) might also have prognostic
value in NHL.
Apart from tumours, high S-TK values are also seen dur-
ing the acute stage of certain viral infections (Gronowitz et
al., 1984) and in megaloblastic anaemia caused by vitamin
B12 deficiency (Hagberg et al., 1984b).
Tbeoretically, elevated S-TK values could, in patients with
a tumour, reflect the tumour burden, the tumour cell pro-
liferation rate or the extent of tumour cell death. High-grade
NHL is often an aggressive, fast-growing disease with a high
rate of proliferation. In contrast, low-grade NHL often has a
slower proliferation rate and a large tumour burden at diag-
nosis. The group as a whole thus comprises lymphomas with
variable proliferation rates and variable tumour burdens.
Both the tumour cell proliferation rate and tumour burden
carry prognostic information (Tubiana et al., 1986; Akerman
et al., 1987; Donhuijsen et al., 1987; Young et al., 1987;
Wooldrige et al., 1988; Rehn et al., 1990a). Tumour cell
death may also carry prognostic information in NHL (Rehn
et al., 1990b).
This study was performed in order to assess the contribu-
tion of the tumour burden and the tumour cell proliferation
rate to S-TK levels and to explore whether C-TK levels
reflect proliferation and carry prognostic information in
NHL.
Maa and mtho-
Patients
Eighty-nine patients with B-cell non-Hodgkin lymphomas (48
with low-grade NHL and 41 with high-grade NHL) were
included in the study. The patient material was consecutive,
provided that frozen tumour cells and serum, taken at dia-
gnosis before treatment was initiated, were available. The
patients were recruited between May 1980 and February
1992. The follow-up times range from 8 to 149 months
(median 102 months). Estimations of S-phase and mitotic
index were available in 67 and 65 patients respectively (Rehn
et al., 1990a, 1991). The lymphomas were classified according
to the Kiel classification (Lennert, 1978) and clinical staging
was performed according to the Ann Arbor system (Carbone
et al., 1971). This staging also takes B symptoms (fever, night
sweats and weight loss) into consideration. The characteris-
tics of the patients in terms of histological group, stage and
age are shown in Table I.
Treatment
The treatment of stage I disease consisted in local extended
radiotherapy in both low- and high-grade NHL. Patients
with high-grade NHL stages II-IV received CHOP (cyclo-
phosphamide, doxorubicin, vincristine, prednisolone) with or
without methotrexate in a randomised trial (Hagberg et al.,
1988) or, after the study was closed, either CHOP or
MACOP-B (methotrexate, doxorubicin, cyclophosphamide,
vincristine, prednisolone and bleomycin; Klimo et al., 1985).
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In patients with stage II-IV low-grade NHL, all treatment
was postponed until symptoms developed. Local symptoms
were treated with radiotherapy and patients with general
symptoms were during the early years randomised to either
intermittent chlorambucil and prednisolone or CHOP
administered in 4 weekly cycles or, in certain instances, to
splenectomy. There was no difference in survival between the
treatment groups (Kimby et al., 1994). Later, this group of
pateints usually received intermittent chlorambucil and pred-
nisolone or, in case of rapidly progressive disease, CHOP.
Preparation oflymph node biopsies
Biopsies arrived in a fresh state. Part of the material was
fixed in neutral buffered formalin for routine histopathology
(hematoxylin-eosin, Giemsa, PAS and Laidlaw stains), and
for silver staining in order to assess the mitotic index (Rehn
et al., 1991); when necessary, immunohistochemical staining
of cytoplasmic immunoglobulins (Martinsson et al., 1985)
was undertaken. Another portion of the material was used
for the preparation of a suspension of cells by mincing the
tissue through a stainless-steel mesh. Part of this cell suspen-
sion was used for immunological phenotyping; part of it was
frozen in liquid nitrogen and later used for measurements of
the S-phase fraction (Rehn et al., 1990a) and C-TK.
Cells to be used for the C-TK measurements were taken
from the liquid nitrogen and thawed in a 37°C water bath,
rinsed at 37°C in culture medium (RPMI + 10% fetal calf
serum + 1% penicillin + glutamine) and then resuspended in
phosphate-buffered saline. The cell number and viability of
the cells (trypan blue exclusion method) was determined.
After centrifugation, the cells were resuspended in a buffer
containing Hepes 25 mM (pH 7.4), magnesium sulphate 2 mM
and bovine albumin 2 mg ml '. Each preparation was
divided into at least two samples and refrozen at - 70°C.
Assay of TKactivity
Determinations of TK levels in serum and cell suspensions
were basically performed according to Gronowitz et al.
(1984). The assay is based on the use of ['"I]iododeoxy-
uridine (IUdR) as a substrate and is available as a kit
(Sangtec Medical, Bromma, Sweden). All TK values are
given as unitsll-l, where 1 unit corresponds to a substrate
turnover of 1.2 x 10-18 katal. The TK activity was deter-
mined directly in undiluted serum, according to the kit insert.
The upper normal limit of S-TK in healthy subjects is
5 unitspl-'.
Determination of TK activity in frozen cell suspensions
was performed, as follows, in order to control the linearity of
the enzyme reaction with time and sample dilution. Frozen
suspensions were thawed, vortexed for 30s and serially
diluted in an ice-bath in five steps in a buffer containing
Hepes 25 mM (pH 7.4), magnesium sulphate 2 mM, A-
lactoglobulin 2 mgml-' and glycerol (25% (v/v). From each
dilution 80p1 was transferred to a new tube, whereafter the
assay was started by adding 2 ml of reaction solution and
transferring the tubes to 37C. The amount of product
formed was determined after 1, 2 and 3 h of incubation, by
transferring 500 1 samples to new tubes containing the
separator. These tubes were further processed according to
the kit insert. The TK activity in each sample was calculated
from the dilutions giving the linear turnover in relation to
time and sample amount. All TK values given refer to at
least two independent determinations on two different
occasions, giving similar results (± 15%). The TK activity in
one million cells was calculated.
S-phasefraction and mitotic index
Estimations of the S-phase fraction and mitotic index were
performed as previously described (Rehn et al., 1990a, 1991).
Twnour volume calculation
A more extended estimation of the tumour burden than that
provided by the clinical stage was performed retrospectively
by calculating the tumour volume (in cm3) from data in the
patient files of findings from clinical examinations, radio-
logical examinations (chest radiography, ultrasonography,
computerised tomography or magnetic resonance imaging of
the abdomen and, in some cases, of the thorax) and bone
marrow examinations (aspirations from the sternum and core
biopsies from the pelvic bones) which revealed the cellularity
and the degree of lymphoma involvement. Clinical examina-
tion, chest radiography, at least one radiological abdominal
examination and bone marrow examination were done in all
patients. If the clinical records did not provide a distinct
assessment of the size of any tumour manifestation, the
X-rays or bone marrow aspirations were re-examined. The
entire bone marrow volume was estimated to 2600 cm3, half
ofwhich was estimated to be red bone marrow (Block, 1976).
Only the proportion of marrow replaced with tumour cells
was included in the tumour volume.
The estimated tumour volumes were grouped into three
categories: small (<50 cm3), medium (50-500 cm3) and large
(> 500 cm3).
Statistical methods
Differences in the distribution of values between two groups
were tested with the Mann-Whitney U-test, and differences
in the distribution of values for several subgroups were tested
with the Kruskal-Wallis test. The correlation between
different parameters was done with Spearman rank correla-
tion test. These tests and the multiple regression calculations
were performed with StatView 4.0 (Abacus Concepts, 1992).
LIFETEST was used to evaluate the prognostic capacity of
the different variables (SAS Institute, 1985). The log-rank test
(Peto et al., 1976) was used. Patients dying of intercurrent
diseases were not included in the population at risk after
their death, provided they were in complete clinical remis-
sion. Best cut-off points were defined as the level yielding the
highest 2-value, when equality over strata was tested with
the log-rank test, provided that at least 15% of the cases had
a value neither below nor above the cut-off level. The
parameters were also tested as continuous variables. Mul-
tivariate analyses with the Cox's proportional hazards model
were performed with Statistica 3.Ob software (Statsoft, 1993).
Chi-square and P-values in the multivariate analyses were
obtained by Wald's test.
Results
C-TK in relation to S-phasefraction, mitotic index,
histopathology and tunour volume
A correlation was seen between C-TK and the two
proliferation-associated parameters, S-phase fraction (r = 0.6,
P= 0.0001) and mitotic index (r = 0.6, P= 0.0001). The cor-
relatin between S-phase fraction and mitotic index was, how-
ever, somewhat higher (r = 0.8, P=0.0001).
High-grade NHL tumours had significantly higher C-TK
values (Table I and II), S-phase fractions and mitotic indices
than low-grade NHL (P = 0.0001 in all cases).
Small and medium-sized tumours also had significantly
higher values of C-TK (P= 0.002) (Table II), S-phase frac-
tion (P= 0.003) and mitotic index (P = 0.01) than large
tumours. An inverse correlation between C-TK and the
numerical value of the tumour volume was seen in all
patients and in high-grade NHL (r = -0.4, P = 0.0001, vs
r = -0.3, P = 0.03). No correlation, however, was observed
in the case of low-grade NHL (r =-0.1, P= 0.65).
When the C-TK levels of the four groups formed from
low- or high-grade NHL together with 'small and medium-
sized tumours' or 'large tumours' were compared, differences
between the groups were seen (P=0.0003, Figure la). In
contrast, when the C-TK values were calculated per cell inTbynlNmS -.
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Table I Patient characteristics and mean values of tumour volume (cm3), S-TK (units idl) and C-TK
(units 10-6 cells) within the different subgroups ofNHL according to the Kiel classification
Stage Tumour
B symptoms I II III IV Age (Years) S-TK vohlne C-TK
Histology n n (%) n n n n Mean Range Mean Mean Mean
Low grade
CLL 20 3 (15) 0 0 1 19 65 (43-84) 15.4 1628 965
IC 7 2 (29) 0 1 0 6 64 (35-85) 8.0 1273 914
CC 2 1 (50) 0 0 0 2 66(53-78) 13.3 939 4425
fCE-CC 14 5 (36) 2 1 3 8 59 (40-81) 9.2 1099 1571
fdCB-CC 5 1 (20) 0 3 0 2 55 (42-71) 11.2 8% 3510
All 48 12 (25) 2 5 4 37 62 (35-85) 12.0 1317 1544
High grade
CB 26 10 (39) 4 3 8 11 61 (25-77) 21.4 424 11213
IB 6 3 (50) 2 0 3 1 68 (37-87) 20.2 500 47%
LB 5 4 (80) 1 0 1 3 39 (12-66) 47.1 259 16160
Unclassif. 4 3 (75) 0 1 1 2 59 (39-68) 73.1 788 4850
All 41 20 (49) 7 4 13 17 59 (12-87) 29.4 450 10256
All 89 32 (36) 9 9 17 54 61 (12-87) 20.0 918 5557
CLL, chronic lymphocytic leukaenia; IC, immunocytic; CC, centrocytic; fCB-CC, follicular
centroblastic-centrocytic; fd CB-CC, foilicular and diffuse centroblastic-centrocytic; CB, centro-
blastic-centrocytic; IB, immunoblastic; LB, lymphoblastic; Unclassif., unasifiable lymphoma.
Table H TK levels in serum (units#I1') and tumour cells (units 1o-6 cells) in relation to histological group and tumour volume
category
S-TK C-TK Correlation S-TKIC-TK
Histology Twnour volume n Mean Median Range Mean Median Range r P
Low grade Small 4 3.0 2.9 1.6-4.8 2825 575 100-10050 0.8 NS
Medium 7 5.2 3.4 1.0-11.3 2136 1500 550-4600 0.5 NS
Large 37 14.2 8.6 2.6-77.0 1293 650 50-8300 0.3 NS
All 48 12.0 6.6 1.0-77.0 1544 675 50-10050 0.2 NS
High grade Small 9 3.7 3.9 1.8-5.0 12583 14775 75-28725 0.5 NS
Medium 21 14.4 9.8 4.2-35.0 12915 7350 750-44700 0.2 NS
Large 11 79.1 51.4 6.2-272.0 3275 3450 250-7650 0.2 NS
All 41 29.4 9.8 1.8-272.0 10256 5250 75-44700 - 0.1 NS
All Small 13 3.5 3.8 1.6-5.0 9581 4350 75-28725 0.6 <0.05
Medium 28 12.1 8.8 1.0-35.0 10220 5113 550-44700 0.4 <0.05
Large 48 29.1 11.1 2.6-272.0 1747 800 50-8300 0.4 <0.01
All 89 20.0 20.1 1.0-272.0 5557 1800 50-44700 0.2 NS
r, Spearman correlation coefficient; NS, not significant.
mitosis or per cell in S-phase, more homogeneous levels were
observed between the four groups (Figure lb and c) with no
statistically significant differences between the groups
(P = 0.3 vs P=0.2). High-grade NHL did not have higher
C-TK levels per cell during mitosis or S-phase than low-
grade NHL. Similarly, the C-TK values per cell in mitosis
did not differ between 'small and medium-sized tumours' and
'large tumours', whereas a borderline significant difference
(P = 0.05) was seen in the C-TK values per cell in S-phase
between 'small and medium-sized tumours' and 'large
tumours'.
Tumour volwne in relation to stage and histopathology
There was a significant difference in tumour volume between
the different Ann Arbor stages (P = 0.0001), although values
overlapped, especially among stages H and m (data not
illustrated).
Low-grade NHL had significantly higher tumour volumes
than high-grade NHL (P =0.0001) (Table 1).
S-TK in relation to histopathology, twnour volume andstage
High-grade NHL had higher S-TK values than low-grade
NHL (P= 0.03) (Tables I and H).
A correlation between S-TK and the numerical value of
tumour volume was seen in all patients (r = 0.4, P = 0.0001)
and in both low-grade NHL (r = 0.6, P = 0.0001) and high-
grade NHL (r= 0.8, P= 0.0001).
The levels of S-TK differed significantly between the
different Ann Arbor stages (P = 0.004; Figure 2a) and the
estimated tumour volume categories (P = 0.0001; Figure 2b).
S-TK in relation to tunour volume and C-TK
Among all patients, there was no correlation between S-TK
and C-TK (r = 0.2, P = 0.06) (Figure 3). All patients with
high S-TK values (>35 unitsILI`) had low or moderately
elevated C-TK values (mean 2902 units 10-6 cells, range
150-7650 units 10-6 cells) whereas all patients with high
C-TK values (>10000 units 10-6 cells) had low or
moderately elevated S-TK values (mean 12.1 units til ', range
3.1-35.0 unitspla-). The former patients had high tumour
volumes (mean 1673 cm3, range 667-3185 cm3), whereas the
latter had low tumour volumes (mean 107 cm3, range
8-325 cm3). Patients with both comparatively low S-TK and
C-TK values had an intermediate mean tumour volume
(993 cm3) but this varied greatly (2-3094 cm3).
In contrast to the lack of correlation between S-TK and
C-TK in all patients, a correlation between S-TK and C-TKTh*mi. kim i Nl.
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was seen within the three tumour volume categories (Table
II). This correlation was not seen within the different stages
according to Ann Arbor (data not illustrated). Within the
different tumour volume categories, the levels of S-TK varied
according to whether C-TK levels were above or below the
median value (Table III). Multiple regression analyses were
performed to evaluate the relative importance of tumour
volume and C-TK for the S-TK level. The values were then
used in a logarithmic form in order to correct for different
scaling. Both tumour volume and C-TK gave significant
contribution to the variations in the S-TK level and the
following relationship was found:
Log S-TK =-0.087 + 0.234 (log tumour volume) +
0.171 (log C-TK)
The equation shows that tumour volume had the strongest
relationship to the S-TK level (P = 0.0001). After the effect
of the tumour volume was taken into account, C-TK also
contributed to the S-TK level (P = 0.009).
B symptoms in relation to histopathology, tumour volwne and
TK levels
Sixty-three per cent (20/32) of the patients with B symptoms
had high-grade NHL. More high-grade NHL patients than
low-grade NHL patients (P = 0.02) (Table I) had B symp-
toms.
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No patient within the small tumour volume category had
B symptoms, whereas almost half of the patients with
medium and large tumour volumes had B symptoms (data
not illustrated).
Patients with B symptoms had significntly higher S-TK
levels (P= 0.002) and slightly higher C-TK values (P= 0.03)
than patients without B symptoms. Of the patients with
medium and large tumour volumes, the patients with B
symptoms had much higher C-TK values (mean 6982 units
10' cells) than patients without B symptoms (mean 3332
units 10-6 cells, P = 0.007).
Relations toprognosis
S-TK, C-TK and tumour volume all carried prognostic in-
formation for the patient sample as a whole (Figure 4), in
patients with low-grade NHL and, with the exception of
C-TK, in patients with high-grade NHL (data not illus-
trated). The separation of the variables into two prognostic
groups is in the case of C-TK, most useful after a short-term
follow-up, and in the case of tumour volume after a long-
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95% confidence intervals.
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Tablem MeanandmedianS-TKvaluesinthedifferent tumourvolumegroups
according to whether C-TK levels were below or above the median C-TK
value
C-TK<180() C-TK 8 1O
Tumour S-TK S-TK
vohine Mean Median n Mean Medin n P-vahle
Small 2.5 2.0 5 4.2 4.6 8 0.02
(n= 13)
Medium 7.0 5.1 7 13.8 9.0 21 0.08
(n = 28)
Large 16.0 8.6 32 55.3 27.4 16 0.003
(n =48)
(P-value') 0.006 0.0001
'Differewe in S-TK according to C-TK keel. 'Difference in S-TK between
tumour volune categories.
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Fuiwe 4 Probability of survival in all patents with NHL
according to (a) S-TK levels [S-TK>20 units ld '(n=2 2); S-
TK<20 units p1- (n = 67), log-rank P =0.00011, (b) C-TK
kvels [C-TK>2550 units 10-6 cells (n = 38); C-TK<2550 units
10-6 cells (n= 51), log-rankr P=0.02] and (c) tumour vohmes
[>1200cm3 (n = 30); <1200cm3 (n = 59), log-rank P = 0.01].
term follow-up, whereas S-TK separates the prognostic
groups after both a short- and long-term follow-up (Figure
4).
Stage also had prognostic value (log-rank P = 0.03),
whereas histological grade provided no prognostic inform-
ation (log-rank P = 0.20). In multivariate analyses involving
Table IV Independent relations to prognosis of S-TK, C-TK and
tumour volume; results ofmultivariate analyses using the variables in
continuous form
Variable p s.e. (P) XI P
(a) Al three variables included
S-TK 0.0091576 0.0031920 8.23 <0.01
C-TK 0.0000343 0.0000189 3.29 NS
Vohlume 0.0002621 0.0001843 2.02 NS
(b) Only two variables included
S-TK 0.0107534 0.0030046 12.81 <0.001
C-TK 0.0000230 0.0000173 1.77 NS
S-TK 0.0098184 0.0032067 9.37 <0.01
Volume 0.0001373 0.0001718 0.64 NS
C-TK 0.0000372 0.0000184 4.09 <0.05
Vohlme 0.0003617 0.0001715 4.45 <0.05
NS, not significant.
S-TK, C-TK and tumour volume (or stage) and the his-
tological grade, S-TK showed superior prognostic strength
and no additional information was provided by any of the
other parameters (data not illustrated).
In order to explore further the relations between S-TK,
C-TK and tumour volume, their association to prognosis was
tested in separate multivariate analyses including all three
variables or only two of them. It was found that neither
tumour volume nor C-TK gave any prognostic information
additional to S-TK (Table MV). In the absence of S-TK,
C-TK and tumour volume each provided additional prognos-
tic information (Table IV). Using log-transformed data or
using the vairables in dichotomised form did not change the
results (data not illustrated).
The prognostic value of S-TK in patients with NHL is well
established (Ellims et al., 1981; Gronowitz et al., 1983;
Hagberg et al., 1984a; Mariinsson et al., 1988; Rehn et al.,
1991). It has been suggested that S-TK reflects both tumour
cell proliferation rate and tumour volume (Rehn et al., 1991;
van der Gaast et al., 1991; Luoni et al., 1991), both of which
are of prognostic importance. The results of this study
strongly suggest that S-TK reflects the tumour volume in
partcular, but also the proliferation rate. In certain other
tumour types, S-TK has also been found to be correlated to
tumour burden and is elevated in higher stages [Simonsson et
al., 1988; Luoni et al., 1991 (multiple myeloma); Eriksson et
al., 1985 (Hodgkin's disease); McKenna et al., 1988; Robert-
sson et al., 1991 (breast cancer); Gronowitz et al., 1986;
Lehtinen et al., 1988; van der Gaast et al., 1991 (small-cell
lung cancer)].
The tumour volume was a good predictor of prognosis,
whereas clinical stage was of less prognostic importance. It is
known that the prognostic importance of the Ann Arbor
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stage, which was orginally developed for HD, is not partic-
ularly strong in NHL (Leonard et al., 1983). Yet, staging
according to Ann Arbor is in routine use as regards therapy
decisions and is used for comparing results from different
trials. This is probably because of its simplicity. Attempts to
replace this staging system by other tumour burden assess-
ments have failed to come in routine clnical use. Since the
tumour burden assessment in this study was performed retro-
spectively, uncertainties may exist, and it is not our intention
to advocate its routine use. However, we beLieve that it
carries some validity, particularly after categorisation into
small, medium and large volumes, in the exploration of the
importance of tumour burden as regards S-TK levels.
C-TK correlated well with other proliferation-associated
factors, supporting the idea based upon theoretical considera-
tions that the level of C-TK reflects proliferation. S-phase
fraction and mitotic index are also, like C-TK, significantly
higher in high-grade NHL than in low-grade NHL. Interest-
ingly, although patient numbers were small within the low-
grade NHL group, the highest C-TK levels were found in the
two groups with an intermediate prognosis, namely cen-
trocytic lymphomas and follicular and diffuse centroblas-
tic-centrocytic lymphomas (Martinsson et al., 1988). The
C-TK level per cell in mitosis (or per cell in S-phase) in
patients with high- and low-grade NHL with 'small and
medium sized' or 'large' tumour volumes, respectively, did
not differ significantly between the groups, indicating that the
content of C-TK in cells in which C-TK is expressed (S-
phase, G2 or mitosis) is very much the same despite the large
variability in proliferation rates.
Even if there was no correlation between S-TK and C-TK
in the patient sample as a whole, the correlations between
these parameters seen within each tumour volumes group
suggest that the S-TK level depends not only upon the
tumour volume, but also upon the cell content of TK, and
thus also reflects cell proliferation. Also, despite significntly
larger tumour volumes in the low-grade NHL group visi--vis
the high-grade NHL, S-TK was significantly higher in
patients with high-grade NHL than low-grade NHL. Multi-
ple regression analyses showed that tumour volume had the
strongest relationship to the S-TK level but that C-TK pro-
vided additional information after the tumour volume was
taken into account. Further support for the importance of
both C-TK and tumour volume as regards the levels of S-TK
comes from multivariate analyses, in which C-TK and
tumour volume showed additional prognostic importance but
neither C-TK, nor tumour volume added any significnt
information to that provided by S-TK.
The finding that the C-TK values were higher in patients
with small or medium-sized tumours (<500 cm3) than in
patients with large tumours probably rlects the fact that
rapidly proliferating tumours become symptomatic much ear-
lier than slowly proliferating ones. In fact, not a single
patient with NHL had both high C-TK and high S-TK levels
at diagnosis. In patients with acute lymphatic leukaemia,
which is usually a highly proliferative disease, very high
S-TK level may be seen (Hagberg et al., 1984c). The C-TK
levels in the tumour cells of patients with ALL collected in
vivo showed levels of the enzyme as high as in high-gade
NHL (Vertongen et al., 1984). It is known that the tumour
volumes in patients with acute leukaemia are generaly higher
than in patients with the closely related lymphoblastic lym-
phoma. Untreated patients suffering from acute leukaemias
have a very short survival, indicating that both high cell
proliferation rate (high C-TK) and a large tumour burden
are incompatible with prolonged life.
This study does not explore how cellular TK reaches the
blood, although one possible explanation may be through
cell death. We have, in a number of patients with NHL, seen
a signifiant increase in S-TK during the days immediately
after chemotherapy administration, with peak levels after
24-48 h (own unpublished observations). The half-life of
S-TK has been estimated to be less than 2 days (Gronowitz
and Killander, 1984). Catalano et al. (1990) have also shown
an increase in S-TK 12-48 h after intensive chemotherapy in
patients with acute myelogenous leukaemia with a reduction
or normalisation, parallel with the blast cell disappearance in
blood, during the following days. Elevated S-TK values are
seen in patients with megaloblastic anaemia as a result of
vitamin Bt2 deficiency (Hagberg et al., 1984c). In that condi-
tion, enhanced TK values are also found in the bone marrow
(Nakao et al., 1968), and it is proposed that the haemolysis
of proliferating immature cells gives rise to the S-TK eleva-
tion (Hagberg et al., 1984c). We therefore suggest that the
level of TK in serum reflects to a great extent the number of
proliferating cells that have died within a few days of the
sampling, even if a release of TK from 'healthy' proliferating
cells cannot be excluded. Bristow et al. (1988) in fact showed
that proliferating cells in culture release TK into the sur-
rounding medium. In studies of liver regeneration in rats,
S-TK and C-TK rise simultaneously (Polimeno et al., 1991).
An elevation of S-TK after liver resections is also seen in
humans (Francavilla et al., 1990).
In tumour sections, areas of tumour cell necrosis are seen
in high-grade NHL but rarely in low-grade NHL (own
unpublished observations). A heterogeneous appearance,
when investigated with magnetic resonance imaging (MRI),
of high-grade NHL, as opposed to low-grade NHL, is most
likely a reflection of tumour cell necrosis (Rehn et al., 1991),
observations indicating cell death in rapidly proliferating
tumours. Preliminary analyses have shown that patients with
stage I disease (often low tumour volume) have a good
prognosis despite the MRI appearance (homogeneous or
heterogeneous), whereas, in stages II-IV, the prognosis is
poorer for heterogeneous tumours (Rehn et al., 1991). These
results thus also fit in with our suggestion.
In conclusion, this study provides evidence that the levels
of TK in serum depend both on the tumour burden and
upon the cellular content of TK, i.e. cell proliferation. This
fact may explain TK's strong prognostic importance in
patients with malignant lymphomas and why it is superior to
most other strong predictors in a number ofstudies (Hagberg
et al., 1984a, Martinsson et al., 1988; Rehn et al., 1991).
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